MEI Pharma Q3 2024 Adj EPS $(1.37) Beats $(1.52) Estimate, Sales $5.890M Beat $37.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
MEI Pharma (NASDAQ:MEIP) reported Q3 2024 adjusted EPS of $(1.37), surpassing the $(1.52) estimate, with sales of $5.890M exceeding the $37.500K forecast by 15.61K percent, a slight decrease from $5.894M in the same period last year.
May 09, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MEI Pharma reported a significant beat on both EPS and sales estimates for Q3 2024, with a minor year-over-year sales decrease.
Beating EPS and sales estimates significantly, especially by such a large margin, is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price. The slight year-over-year decrease in sales is noted but is overshadowed by the substantial beat on expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100